Becton, Dickinson and Company Operating Income decreased by 83.2% to $93.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 75.7%, from $383.00M to $93.00M. Over 4 years (FY 2021 to FY 2025), Operating Income shows an upward trend with a 3.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Growth in operating income suggests that the core business is becoming more profitable and efficient.
The profit realized from a business's own operations after deducting operating expenses like wages, depreciation, and co...
This is a key metric for comparing the fundamental business performance of companies with different tax or debt structures.
operating_income| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $492.00M | $83.00M | $692.00M | $564.00M | $537.00M | $489.00M | $585.00M | $628.00M | $549.00M | $349.00M | $439.00M | $734.00M | $602.00M | $622.00M | $453.00M | $383.00M | $882.00M | $861.00M | $552.00M | $93.00M |
| QoQ Change | — | -83.1% | +733.7% | -18.5% | -4.8% | -8.9% | +19.6% | +7.4% | -12.6% | -36.4% | +25.8% | +67.2% | -18.0% | +3.3% | -27.2% | -15.5% | +130.3% | -2.4% | -35.9% | -83.2% |
| YoY Change | — | — | — | — | +9.1% | +489.2% | -15.5% | +11.3% | +2.2% | -28.6% | -25.0% | +16.9% | +9.7% | +78.2% | +3.2% | -47.8% | +46.5% | +38.4% | +21.9% | -75.7% |
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| BioPharma Systems | $602.00M | $622.00M | $453.00M | $383.00M | $882.00M | $861.00M | $552.00M | $93.00M |
| Connected Care | $602.00M | $622.00M | $453.00M | $383.00M | $882.00M | $861.00M | $552.00M | $93.00M |
| Interventional | $602.00M | $622.00M | $453.00M | $383.00M | $882.00M | $861.00M | $552.00M | $93.00M |
| Life Sciences | $602.00M | $622.00M | $453.00M | $383.00M | $882.00M | $861.00M | $552.00M | $93.00M |
| Medical | $602.00M | $622.00M | $453.00M | $383.00M | $882.00M | $861.00M | $552.00M | $93.00M |
| Medical Essentials | $602.00M | $622.00M | $453.00M | $383.00M | $882.00M | $861.00M | $552.00M | $93.00M |
| Total | $602.00M | $622.00M | $453.00M | $383.00M | $882.00M | $861.00M | $552.00M | $93.00M |